Governance :

Risk Management

リード文

We are aware that major risks may occur, which is why we have established a system that not only prevents the occurrence of such risks, but also takes appropriate measures to deal with them should they occur. In an aim to realize optimal company-wide risk management, we have established the Risk Management Global Policy and introduced Enterprise Risk Management (ERM).

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Risk Management

Basic Policy for Enterprise Risk Management (ERM)

  • In order to ensure the company's stable business continuity and to achieve our business goals, we will develop and promote an Enterprise Risk Management (ERM) System with the aim of minimizing losses for the company, our customers and other stakeholders while at the same time fulfilling our necessary accountability to society.
  • We will identify major risks that are deemed important or urgent as having a significant impact on management, and promote risk management throughout the company.
  • If a risk emerges, we will implement measures to minimize damage and swiftly recover, and resolve the problem as soon as possible.

ERM Promotion System

We have established our ERM System with the Representative Director, President & COO as Chief Risk Management Officer responsible for ERM, and Representative Director, Executive Vice President / Executive Director, Corporate Strategy & Planning as Head Risk Management Officer, and as we regard risk management issues as important issues for our business strategy, we are taking action to respond to those issues. In addition, a Risk Management Committee has been established under the Management meeting to promote ERM, mainly led by the Risk & Compliance Management Department, which is the department (secretariat) in charge of risk management. Moreover, the Audit & Supervisory Boards and the Internal Audit Department are responsible for auditing the status of ERM promotion. Our Audit & Supervisory Board consists of two full-time Audit & Supervisory Board Members, who are well-versed in all aspects of our business operations and possess advanced information-gathering capabilities, and two outside Audit & Supervisory Board Members, who provide highly independent, objective, and professional perspectives. The Board conducts audits from a position independent of management. The Risk Management Committee also regularly reports the results of company-wide risk assessments and the status of responses to risks to the Board of Directors in an effort to improve the effectiveness of risk management.

ONO’s risk management system

  • 1st Line: Role in business promotion and risk management practices
  • 2nd Line: Role in monitoring and keeping 1st Line activities in check
  • 3rd Line: Role in providing independent assurance
Crisis management

In the event that a serious risk does emerge, the Representative Director, President & COO will establish an Emergency Response Committee, as necessary, to take measures to minimize damage and promote a speedy recovery.

Auditing of risk management process

Auditors conduct audits every year on our risk management process. In addition, the Risk Management Committee Secretariat reports semiannually to the Audit & Supervisory Boards (including two outside auditors) twice a year on the status of ERM, including risk identification (methods and results), risk assessment (priority rating), responses to major risks, and the results of those responses, among other matters. Furthermore, with regard to internal operational audits, the Risk Management Committee Secretariat shares with the Internal Audit Department the status of operational risk management confirmed by each division and the occurrence of new risks as needed, and this information is reflected in the selection of items for operational audits. The Internal Audit Department regularly reports the results of audits to the Audit & Supervisory Boards.

Involvement of Outside Directors in Risk Management

Outside directors are expected to serve the roles of supervising and advising management.
They are regularly reported on risk management at meetings of the Board of Directors, review the management system, and operation of ERM, and provide advice as needed.
They also regularly exchange opinions with the Risk Management Committee secretariat outside meetings of the Board of Directors. They provide advice on a wide range of ERM topics, based on the experience of corporate executives and professor (business administration), and keep their knowledge up to date on risk management practices.

Risk management education

Our training on risk management is conducted through a combination of level-specific and theme-specific training to ensure that all employees understand the importance of risk management and to enhance the effectiveness of our risk prevention activities. In our level-specific training, we provide training programs tailored to the roles and attributes of participants, such as executives and newly appointed managers.

  • As an example of our hierarchical training programs for FY2024, we held a session for executives led by an external instructor on “Essential Risk Management Points for Executives.” This training covered the responsibilities and roles of management in risk management, provided a refresher on our company’s ERM framework, and addressed risk management practices aimed at helping each division and department achieve their goals.

In our theme-specific training, we regularly conduct e-learning twice a year, in the first and second halves of the year, on the basics of compliance, which is basic information that every employee should know as a member of society. This is done in an effort to foster a corporate culture within the company.

  • In FY2024, we provided an overview of our risk management initiatives along with fundamental knowledge, and focused on sharing specific actions for daily operations.
Group-company-wide Risk Management

While respecting the autonomy of each group company, we provide advice and guidance on group-wide risk management through means such as periodic reports on business activities and discussions regarding important matters. Since FY2020, we have been expanding our ERM System to our group company in Japan and overseas, and have been using the “Risk Assessment Sheet” in our operations since FY2021. From FY2024, we have expanded the scope of our initiatives to include group companies engaged in businesses other than pharmaceuticals. We are continuously implementing risk management measures tailored to the specific circumstances of each group company, working to strengthen the overall risk management framework across the entire group.

Annual Cycle of Risk Management

We strive to continuously improve ERM through the following four processes: First, we clarify the purpose of ERM for strengthening our management foundation, the target risks, and preconditions such as common risk evaluation criteria for the entire company (Step 1). Next, we conduct semiannual risk hearings with each division and department twice a year to identify potential risks and reassess existing risks, and formulate and update plans for dealing with those risks. We also conduct interviews with management to identify key risks that should be managed on a company-wide basis (Step2). Each risk is scored based on its likelihood and impact, and then classified as critical, high, medium, or low. Risks rated as high or above are considered particularly important from a management perspective, designated as “company-wide risks” by the Risk Management Committee, and are given priority for countermeasures(Step 3). For each company-wide risk, a risk owner is selected for each risk to be responsible for managing those risks, and the progress of response plans is monitored by the Risk Management Committee twice a year. These updates are also reports to the Board of Directors (Step 4). We are working to enhance corporate value through the promotion of these ERM initiatives.

figure
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Business Continuity Plan (BCP)

We have established a Business Continuity Plan (BCP) to ensure that, even if our operations are interrupted by natural disasters or accidents, we can quickly recover and resume our business operations. By securing two production sites—Fujiyama Plant and Yamaguchi Plant—and multiple logistics centers across Japan, we are working to mitigate risks and ensure a stable supply of our products. At key locations such as our headquarters, Tokyo Building, each plant, and each research institute, we have implemented disaster countermeasures, including emergency power supply systems and redundant power lines to protect against power outages. In addition, we have installed seismic isolation systems at our headquarters, Tokyo Building, Minase Research Institute, and Yamaguchi Plant to reduce the risks associated with earthquakes. Furthermore, to prepare for large-scale disasters, we have established a system that allows us to respond from both our headquarters and the Tokyo Building, implemented a system to quickly confirm the safety of our employees, and continue to strengthen our response capabilities through improvements to our internal systems and regular training.
The BCM Committee, which is responsible for business continuity management, is working to develop an all-hazards BCP that addresses not only natural disasters and major accidents but also a wide range of potential incidents. Furthermore, we are developing crisis response and business continuity plans on a global scale, including our overseas group companies.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Major Risks

The Ono Pharmaceutical Group's performance may be significantly affected by various business development risks that may arise in the future. The following is a list of major potential risks to the group's business development efforts. However, this is not an exhaustive list of every risk, and risks other than those listed may also exist, which may affect investors' decisions. Furthermore, items regarding future matters in the text were decided on by the Ono Pharmaceutical Group as of the end of FY2024.

Risks are classified into three categories, namely, “Strategic Risk,” “External Risk Factor,” and “Operational Risk(Risks associated with business operations),” and basic policies and priorities for dealing with those risks have been determined. The basic policy for responding to each risk classification is as follows:

  • Strategic Risk: A risk associated with the business itself, such as failed business plans, which should be addressed in medium-term plans, etc.
  • External Risk Factor: A risk arising from external factors that cannot be managed and should be addressed through ERM, including BCP.
  • Operational Risk: A risk that arises through management failures that could have been avoided if imagination was used, and should be addressed through ERM.

Based on these three categories, our “major risks” are as follows:

  1. New Product Development
    • Main Risk Item: Failure to develop new products
    • Risk Classification: Strategic risk
    Based on our corporate philosophy of “Dedicated to the Fight against Disease and Pain,” we aim to establish ourselves as an R&D-based global pharmaceutical company (Global Specialty Pharma) that is capable of competing on the global arena by discovering original and innovative drugs that truly benefit patients in order to meet unmet medical needs. To this end, we are taking on the challenge of creating innovative drugs on our own and actively promoting open innovation to incorporate the world's most advanced technologies and know-how.
    However, it is also expected that long-term and large R&D investments may not yield results, and that development may have to be suspended, resulting in the failure of bringing new and original drugs to the market. In the event of such a situation, our group's business results and financial standing may be significantly impacted as we would not be able to generate the future earnings we had originally expected.
  2. Overseas Business Expansion
    • Main Risk Item : Failure to market our own products in the West
    • Risk Classification: Strategic risk
    The Ono Pharmaceutical Group is working to expand its business overseas with the aim of becoming an R&D-based global pharmaceutical company (Global Specialty Pharma) that is capable of competing on the global arena by discovering original and innovative drugs. We have already established local subsidiaries in South Korea and Taiwan to market our own products, and are currently working to develop and strengthen our development and self-marketing systems, etc. in the West. In June 2024, we welcomed Deciphera Pharmaceuticals, Inc. (Deciphera), which possesses excellent R&D capabilities in the field of oncology and commercial capabilities in the West, as a Group company to accelerate our group’s pipeline expansion and global development.
    As we engage in our global business activities, we consider necessary measures such as addressing development risks by expanding our development pipeline to offer multiple product candidates for release, as well as obtaining information on legal regulations, economic conditions, political instability, region-specific natural disasters and uncertainties in the business environment in each country. However, our group's business results and financial standing may be affected if we are not able to completely avoid risks.
  3. Dependence on Certain Products
    • Main Risk Item: Failure to break away from dependence on specific products
    • Risk Classification: Strategic risk
    Revenues from Opdivo I.V. infusion and royalties related to anti-PD-1/PD-L1 antibodies account for approximately the mid-50% range of our group's total revenue (fiscal year ending March 2025). The Ono Pharmaceutical Group's business results and financial standing could be affected if sales revenues decline due to NHI drug price revisions, the emergence of other strong competitor products, the expiry of patents or other protection periods, and/or other unforeseen circumstances.
    To address such risks, the Ono Pharmaceutical Group is working to accelerate the global expansion of its business in its medium-term management plan, which has been in development since FY2017. Until now, our business model has been based on conducting clinical development and sales in Japan, Korea, and Taiwan, and licensing out new drug candidates in Europe, the United States, and other regions. However, we are working to change that model and conduct our own clinical development and marketing in Europe and the United States. As part of this effort, in June 2024, we acquired the US biopharmaceutical company Deciphera, which strengthened our clinical development system in Europe and the United States, and allowed us to acquire sales networks in more than 40 countries around the world. Moving forward, we will work to swiftly improve our once Opdivo-dependent management structure by quickly introducing our assets in the clinical development stage to the global market. This includes, but is not limited to, Qinlock and Romvimza (assets held by Deciphera), Velexbru (a drug created by Ono Pharmaceutical), and Sapablursen (a drug introduced by Ionis in March 2025).
  4. Compliance
    • Main Risk Items: Pharmaceutical and Medical Device Act violations, Anti-bribery laws and regulations violations, antitrust laws violations, Code of Practice violations
    • Risk Classification: Operational risk
    In conducting our business activities, our group is subject to various laws and regulations, including those related to product quality, safety, the environment, and chemical substances, as well as those related to transactions, labor, accounting standards, and tax laws. We will also need to respond to stronger national policies, laws and regulations for mitigating climate change. In the event of a serious breach of the law by the Ono Pharmaceutical Group or its contractors, etc., the group's reputation, business results and financial standing may be affected. The group's business results and financial standing may also be significantly affected if changes to laws and regulations restrict its business activities and if investments are required to deal with such changes.
    The group has established a compliance management system based on the Ono Group Code of Conduct, which includes enacting policies such as the Compliance Global Policy, and establishing a Group Compliance Committee and a compliance violation reporting service both within and outside the company. Furthermore, we have established a system to prevent violations by identifying and monitoring compliance risks on a regular basis to ensure compliance with laws and regulations relating to our business activities.
  5. Product Quality Control
    • Main Risk Item: Product defects and recalls
    • Risk Classification: Operational risk
    In order to provide a stable supply of quality medicines, not only from the perspective of legal requirements relating to the quality of medicines, but also from the perspective of patients, caregivers, and healthcare professionals, our group has a policy of ‘contributing to society through the stable supply of medicines with a high level of quality assurance’, and based on this policy and our company’s own quality manuals, we have established a quality system and are working to continuously improve the system. However, in the event of unexpectedly serious quality-related issues or concerns over product safety and security or product liability (PL) issues due to new scientific findings, this could lead to liability for damages and a loss of trust not only in the product brand in question, but also in the group as a whole, and the group's business results and financial standing could be significantly affected.
    If there are concerns about the quality, effectiveness or safety of our products, the Ono Pharmaceutical Group promptly assesses those concerns, and if a decision is made to recall the concerned products, information is promptly provided to healthcare professionals who then recall the products in question.
  6. Supply Chain (Stable Supply)
    • Main Risk Item: Supply chain risks
    • Risk Classifications: External risk factor, operational risk
    The Ono Pharmaceutical Group has established a system to deal with the risk of natural disasters and accidents, as well as the risk of deviating from the Pharmaceutical and Medical Device Act.
    However, our group's business results and financial standing could be affected if our production activities are stagnated or delayed due to the suspension of the functions of certain plants or external contractors, or if the supply of raw materials from suppliers is halted due to natural disasters such as earthquakes and typhoons, the spread of a large-scale infectious disease, accidents such as fires, system failures or terrorist attacks, or if there is a deviation from the Pharmaceutical and Medical Device Act. Details regarding measures to deal with natural disasters and accidents are described in (13) Natural Disasters (Major Earthquakes and Climate Change), Infectious Diseases, and Accidents.
    In order to address the risk of deviating from the Pharmaceutical and Medical Device Act, we have established strict in-house quality standards and thoroughly implement production-related documentation and verification, change control, and deviation management processes. We also conduct quality audits on our own factories and contractors and regularly check that they are operating appropriately. Furthermore, we recommend employees to act from a patient-oriented perspective and to promptly report and share information whenever they feel that something is wrong. This is being done in an effort to foster and establish a culture of quality, and we ask our contractors to do the same. In this manner, we ensure a consistent high standard of quality control to make sure that products that do not conform to our standards are never shipped.
  7. New Side Effects
    • Main Risk Items: Occurrence of new side effects, etc.
    • Risk Classification: Strategic risk
    Medical products have the potential for new side effects, which were not experienced during the clinical trial phase, to be reported after they hit the market, or the frequency of those side effects may increase. If a new serious side effect does occur, the group's business results and financial standing could be affected by the payment of compensation for damages or a decrease in sales revenue due to the withdrawal of approvals, etc.
    Our group has developed risk management plans for each of its medicinal products and continuously collects and assesses safety (adverse drug reaction) information. After assessing the collected information for seriousness and the need for alerts, we implement safety measures as necessary, such as revising package inserts and providing notices on the proper use of our medical products, etc.
  8. Responding to Changes in the Market Environment (Changes in the Competitive Environment & Healthcare Reforms)
    • Main Risk Items: Increased competition from competing products and generics, and failure to respond to medical cost control measures
    • Risk Classifications: Strategic risk, external risk factor
    The Ono Pharmaceutical Group's pharmaceutical manufacturing and sales business is subject to various regulations by the pharmaceutical administration of each country. Our group's business results and financial standing could be affected if sales revenue declines due to changes in the pharmaceutical market environment, such as the sales status of competing and generic products, as well as due to the effects of healthcare reforms in Japan, such as reductions in official NHI drug prices and the promotion of generic drug use, or due to various medical cost control measures implemented overseas.
    In response to this, the Ono Pharmaceutical Group is working to maximize product value through proactive R&D activities and the swift reinforcement of company-wide cross-divisional collaboration. In addition to promptly detecting and responding to changes in the healthcare system, we are also taking a strategic approach to ensure our competitive advantage by anticipating changes in the market environment from the early stages of development. At the same time, we also constantly monitor market trends in aspects that affect our products’ life cycles and prepare resources to maximize the potential of our products.
  9. Information Security
    • Main Risk Items: Cyber attacks, unauthorized access, and leakage of personal information from external parties
    • Risk Classifications: External risk factor, operational risk
    The Ono Pharmaceutical Group promotes the use of digital and IT not only to improve the efficiency and sophistication of its operations, but also to enable a more flexible corporate transformation that is in line with the business environment. In addition, highly confidential and personal information is handled by these systems. Things get more complex as our business becomes increasingly global and as the scope of how data is utilized expands, and so, there is a risk of possible technical failures, suspension of business operations due to unauthorized access or attacks from third parties or from within the company, and leakage of critical information.
    For these reasons, if information is tampered, misused or leaked, etc., due to a system failure or accident caused by a computer virus infection, cyber attack or other cause, the group's business results and financial standing may be affected due to reasons such as a significant loss of public trust.
    To reduce these risks, in addition to the development of security-related policies and guidelines and the use of appropriate technological countermeasures and services in line with changes in the social environment, we have established an incident response system and provide training for all employees in Japan and overseas, and continually reinforce measures based on security assessments conducted by third parties.
  10. Recruitment, Training, and Retention of Human Resources
    • Main Risk Items: Delays in the recruitment, training, and retention of human resources
    • Risk Classification: Strategic risk
    The Ono Pharmaceutical Group strives to recruit, train and retain a diverse and talented workforce for sustainable growth, but if we are unable to recruit, train and secure diverse and talented personnel over the medium to long term, our business activities may stagnate, etc., and the group's business results and financial standing may be significantly affected.
    In order to ensure that each and every member of our diverse pool of talent can work energetically and demonstrate their full potential, we are developing systems and work environments that enable our employees to work in diverse ways. We are also working to recruit and secure human assets through initiatives aimed at making our company a rewarding and attractive place to work, and are enhancing our training systems and creating opportunities for employees to take on the challenge of furthering their individual growth and developing their skills.
    Furthermore, in order to respond swiftly and flexibly to changes in the environment and to increase our corporate value, we place importance on increasing the diversity of our human resources while at the same time fostering a climate of mutual respect. From the perspective of diversification in terms of age, gender, and corporate history, the hiring of young, female and mid-career employees is being promoted at the management level, which spearheads business growth. In addition to this, by utilizing our company’s engagement surveys, we are promoting the development of a climate where our diverse workforce can stay highly motivated as they engage in their respective tasks.
  11. Intellectual Property
    • Main Risk Items: Infringement on the intellectual property of a third party, infringement of intellectual property from a third party
    • Risk Classification: Operational risk
    The Ono Pharmaceutical Group takes great care to ensure that the products it manufactures and sells do not infringe the intellectual property rights of third parties, but in the unlikely event of an infringement, our group's business results and financial standing could be affected by a decrease in sales revenue, etc., due to the payment of compensation for damages or a suspension of manufacturing and sales.
    Although the group appropriately determines and manages inventors and other parties, and pays them appropriate compensation as stipulated in our internal regulations and contracts, etc., the group's business results and financial standing could be affected by the payment of compensation for damages if it is sued by an inventor or other party.
    Furthermore, if intellectual property rights owned by the group or licensed from other companies are infringed by a third party, the group's business results and financial standing could be affected by the loss of expected earnings.
  12. Handling of Impairment Risks (Sales Rights, In-Process R&D Expenses, and Goodwill)
    • Main Risk Item: Occurrence of huge impairment losses
    • Risk Classification: Strategic risk
    The Ono Pharmaceutical Group monitors its performance by comparing budgets with actual results, as well as other means, and has established a system to measure impairment losses in a timely manner if there are signs of a deterioration in performance. In the future, if deviations from the performance plan occur and the expected future cash flow cannot be obtained due to the emergence of various risks, etc., described in “Business and other risks,” impairment losses on sales rights, in-process R&D expenses, and goodwill could be incurred. In such cases, the group's business results and financial standing may be affected.
  13. Natural Disasters (Major Earthquakes and Climate Change), Infectious Diseases, and Accidents
    • Main Risk Items: Natural disasters and accidents
    • Risk Classification: External risk factor
    Problems may arise in securing raw materials, continuing production, distribution processes, etc., due to a major earthquake, a natural disaster associated with climate change, or the spread of large-scale infectious diseases, etc. Alternatively, explosions and fires at production plants, failures in information and control systems, malfunctions in social infrastructure such as electricity and water, environmental pollution caused by hazardous substances, terrorism, political turmoil, riots and other events may occur. For these reasons, if the supply of manufactured goods or research and development activities, etc. are hampered, our group's business results and financial standing may be affected due to the stagnation of our business activities, etc.
    Even if business is interrupted, the Ono Pharmaceutical Group has formulated business continuity plans (BCPs) to ensure that it can promptly restore and resume operations in the event of accidents and natural disasters such as earthquakes and climate change-related flooding. By securing our two production sites, namely, the Fujiyama Plant and the Yamaguchi Plant, as well as distribution hubs in several locations in Japan, we reduce risks that pose a threat to the stable supply of our products. As part of our disaster prevention measures, the head office, the Tokyo building, each plant and each research center, which are all important sites, are equipped with emergency power supply equipment, redundant power supply lines, and other equipment to deal with power outages. In addition, seismic isolators have been installed at the head office, Tokyo Building, Minase Research Institute and Yamaguchi Plant to reduce the risks associated with earthquakes. In preparation for large-scale disasters, we are working to develop internal systems, such as building a system that can respond to such disasters through two locations, namely the head office and Tokyo building, and introducing a system that can quickly confirm the safety of our employees. We are also continuously working to strengthen our contingency response capabilities by regularly implementing disaster drills and other activities. The BCM Committee, which is responsible for business continuity management (BCM), is working to develop an all-hazards approach BCP that can respond to various incidents as well as natural disasters and major accidents. The BCM Committee is also developing global emergency response plans and BCPs, including for overseas subsidiaries.
  14. Fluctuations in Financial Market Conditions
    • Main Risk Items: Exchange rate fluctuations, changes in the price of financial assets
    • Risk Classification: External risk factor
    • Exchange rate fluctuations
      As the Ono Pharmaceutical Group internationally expands its business and receives royalties and pays expenses in foreign currencies, etc., we are exposed to the risk that fluctuations in exchange rates may reduce sales revenue, increase purchase costs and research and development costs, and incur foreign exchange losses. In order to mitigate the above risks, our group hedges a certain percentage of foreign currency transactions with forward exchange contracts in accordance with our market risk management policy. However, our group's business results and financial standing could be affected if foreign currency exchange rates fluctuate greater than expected.
    • Price fluctuations
      The Ono Pharmaceutical Group is exposed to the risk of stock price fluctuations arising from capitalized financial instruments. The Ono Pharmaceutical Group does not hold any capitalized financial instruments for short-term trading purposes but holds capitalized financial instruments to smoothly execute its business strategy. Our group regularly assesses the fair value of such instruments and the financial status of their issuers, etc., and reviews their holdings as necessary while taking into account our relationship with relevant companies. However, our group's business results and financial standing could be affected if the fair value of capitalized financial instruments changes significantly beyond expectations.
  15. Addressing Environmental Issues
    • Main Risk Items: Increased costs of measures against global warming, the occurrence of environmental pollution accidents
    • Risk Classifications: External risk factor, operational risk
    To address environment-related issues, the Ono Pharmaceutical Group has established its environmental challenge vision (ECO VISION 2050) based on its environmental global policy, and the group is making company-wide efforts to realize a decarbonized society, a water recycling society, and a resource recycling society. In addition, based on the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and the Taskforce on Nature-related Financial Disclosures (TNFD), we disclose information after considering how to identify and respond to risks related to climate change and nature. In this manner, our company recognizes its corporate social responsibility towards the environment and promotes environmentally friendly activities in all areas of its business activities to preserving the rich global environment.
    Some chemicals substances and biological samples used in pharmaceutical research, manufacturing processes, etc., have a significant impact on human health and ecosystems and therefore need to be appropriately managed. The Ono Pharmaceutical Group not only complies with relevant laws and regulations regarding the use, manufacturing, storage, disposal and other handling-related matters for hazardous substances in the countries and regions where we operate, but we have also established voluntary standards that are stricter than laws and regulations and implement proper management through monitoring.
    However, if future revisions to environment-related laws and regulations impose stricter requirements, the costs for addressing those requirements may increase and our research, development, manufacturing and other business activities may become restricted. In the unlikely event of non-compliance with environment-related laws and regulations, unexpected environmental pollution caused by hazardous substances, and if the associated harm becomes apparent, these developments could undermine the public’s trust in our company, potentially excluding us from insurance coverage, or causing us to be liable for costs and legal liabilities in excess of the compensation amount. In such cases, the group's business results and financial standing may be affected.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Information Security Management

Basic Approach

Information assets are very important management resources.
We established a global policy on information security to protect information resources strictly, including data related to research and development and the personal information of internal and external stakeholders, and to manage the information appropriately. In consideration of the global increase in cyberattacks and security threats, we are also addressing the further strengthening of cybersecurity based on the global standard framework.

Information Security Management System

We have established Information Security Global Policy and procedures, as well as an information-security-related management system to ensure the effectiveness of these policies and procedures.
Overall responsibility for information security rests with Risk Management officer of Digital Technology (Executive Director of Digital Technology). The Risk Management officer of Digital Technology is responsible not only for formulating the ONO Group’s information security management strategy, but also for creating, revising, implementing and managing related policies, etc., and for ensuring that the ONO Group complies with them, while taking into account changes in the environment surrounding Ono Pharmaceutical and the latest trends in relevant laws and regulations, etc. Under the Risk Management officer of Digital Technology, a Head of Information System Department of the Company and the Information Security Department Manager are appointed to perform information security management duties at each division and Group company*.
Initiatives related to information security and cybersecurity are reported and shared at the Board of Directors following the Digital Technology Division meeting and the Risk Management Committee.

  • A company of which 100% of voting rights are owned by ONO PHARMACEUTICAL CO., LTD.

Organizational Structure for Information Security Management

Click here for our Privacy Policy.

Cyber Security Measures

Cyberattacks are becoming increasingly sophisticated and complex, so in response to these changes in the external environment, we continuously review and improve measures to address this issue. Some specific examples of such measures include implementing multi-layered defenses, strengthening our global security infrastructure, thoroughly enforcing policies, and conducting periodic vulnerability assessments.

Responding to Security Incidents

We have organized a Computer Security Incident Response Team (CSIRT) for the purpose of quickly resolving security incidents and minimizing damage. The CSIRT strives to maintain and improve the security level of the entire group by collecting vulnerability and threat information and issuing alerts. In addition to conducting regular incident response training, the CSIRT also actively collects and shares information by participating in security organizations and communities.

Security Education & Awareness

In order to prevent security incidents from occurring, it is important to not only implement technical countermeasures but to also raise the security awareness of each and every employee. That is why we regularly educate our employees on information security and conduct e-mail training on a global basis. We have also established a website to disseminate information related to information security, and are making efforts to explain and inform our employees about various guidelines and rules on information security.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system